Last reviewed · How we verify
Tandospirone + Amlodipine
Tandospirone acts as a 5-HT1A receptor agonist for anxiety, while amlodipine is a calcium channel blocker for hypertension and angina.
Tandospirone acts as a 5-HT1A receptor agonist for anxiety, while amlodipine is a calcium channel blocker for hypertension and angina. Used for Generalized anxiety disorder, Hypertension, Angina pectoris.
At a glance
| Generic name | Tandospirone + Amlodipine |
|---|---|
| Sponsor | Chongqing Medical University |
| Drug class | 5-HT1A agonist + dihydropyridine calcium channel blocker |
| Target | 5-HT1A receptor; L-type calcium channel |
| Modality | Small molecule |
| Therapeutic area | Psychiatry/Neurology; Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
This is a fixed-dose combination where tandospirone selectively binds to serotonin 5-HT1A receptors in the brain to reduce anxiety symptoms, while amlodipine blocks L-type calcium channels in vascular smooth muscle and cardiac tissue to lower blood pressure and improve coronary blood flow. The combination addresses both anxiety and cardiovascular conditions in a single formulation.
Approved indications
- Generalized anxiety disorder
- Hypertension
- Angina pectoris
Common side effects
- Dizziness
- Headache
- Peripheral edema
- Fatigue
- Nausea
Key clinical trials
- Comparison of Tandospirone, Amlodipine and Their Combination in Adults With Hypertension and Anxiety (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tandospirone + Amlodipine CI brief — competitive landscape report
- Tandospirone + Amlodipine updates RSS · CI watch RSS
- Chongqing Medical University portfolio CI